Overview of Furoxone

Property	Description
Active Ingredient	Furazolidone
Forms	Tablet, Oral Suspension
Pharmacological Class	Antimicrobial Agent, Nitrofuran
General Purpose	To fight bacterial and protozoal infections
Origin	Synthetic

What is Furoxone and its Chemical Origin?

Furoxone is the former brand name for a medicine containing the active ingredient Furazolidone, a synthetic compound classified as an antimicrobial agent. This compound is chemically known as a nitrofuran derivative, a specific organic molecule that possesses an essential furan ring structure. Furazolidone is consistently prepared as a single-ingredient product, typically functioning as a prescription-only (Rx) medication.

This synthetic origin is crucial to its nature, as the compound is specifically designed and supported by pharmacological studies to target infectious organisms systematically. This distinguishes the nitrofuran derivative from antibiotics derived from natural biological sources.

The Pharmacological Type: Antibacterial and Antiprotozoal

Furazolidone is categorized as an anti-infective agent with broad-spectrum capability, allowing it to function as both an antibacterial and an antiprotozoal drug. This dual action is a key differentiator, as many common anti-infectives target only one of these pathogen types. The broad-spectrum utility is clinically recognized for addressing infections where both bacteria and protozoa may be causative agents.

Its utility is primarily systemic, aimed at eliminating or inhibiting the growth of these invading microorganisms. This confirms the medicine's role in clearing infections, for instance, in cases of infectious diarrhea.

Available Forms of Furazolidone (Tablets and Suspension)

Furazolidone is administered through the oral route, meaning it is taken by mouth, and has historically been supplied in two main oral dosage forms: a solid tablet and an oral suspension (liquid). The preparation in these two different forms ensures the medication is suitable for various patient needs, particularly making the liquid oral suspension a practical option for the pediatric patient group. These preparations allow the active ingredient to be delivered systemically to the body, facilitating its broad-spectrum action against susceptible pathogens.

What side effects are possible with Furoxone?

Furoxone: Possible Side Effects and Safety Information

The safety profile of Furoxone (furazolidone) is based on reported adverse reactions and specific regulatory limitations, particularly concerning drug and food interactions, patient population, and long-term toxicity findings.

Adverse Reactions and System Involvement

Adverse reactions commonly affect the gastrointestinal system (e.g., nausea, vomiting, abdominal pain, diarrhea) and may be reduced by dose adjustment. Less common reactions include hypersensitivity reactions such as fever, rash, itching, joint pain (arthralgia), and a drop in blood pressure (hypotension). Other documented reactions involve the nervous system (e.g., headache, malaise) and may cause a disulfiram-like reaction (e.g., flushing, chest constriction) if alcohol is consumed.

Serious Safety Concerns and Restrictions

Monoamine Oxidase (MAO) Inhibition: The medicine carries a risk of hypertensive crisis—a severe increase in blood pressure—due to its MAO-inhibiting activity. This risk requires strict avoidance of tyramine-containing foods (e.g., aged cheeses, yeast extracts) and certain indirectly acting sympathomimetic amines (found in many decongestants and appetite suppressants). This restriction must be maintained for at least two weeks after treatment discontinuation.

Hematologic Risk: The drug should not be administered to infants under one month of age due to the possibility of causing hemolytic anemia (destruction of red blood cells) from immature enzyme systems. Mild, reversible hemolysis may also occur in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency; the medicine must be discontinued if this occurs.

Animal Toxicity Findings: Regulatory documents note evidence of tumorigenic activity (causing tumors) in chronic, high-dose oral studies in rodents, and it is a suspected reproductive toxicant. The relevance of these findings to short-term human use is not established, but this information places restrictions on its long-term or chronic use.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation describes the signs and required actions associated with an overdosage of Furoxone (Furazolidone). This information is based strictly on documented clinical manifestations and regulator-mandated emergency procedures.

Documented Manifestations and Risks

Classification	Official Regulatory Statement
Neurological Toxicity	Overexposure may result in systemic toxicity, presenting with tremors, convulsions, and peripheral neuritis. Other documented signs include dizziness and headache
Pharmacological Risk	The drug’s monoamine oxidase inhibitor (MAOI) property creates a theoretical risk of a severe hypertensive crisis if large quantities are ingested.
Hematologic Vulnerability	Patients with G6PD deficiency and infants up to one month of age face an increased risk of hemolytic anemia in overexposure scenarios.
Gastrointestinal	Documented manifestations include nausea and vomiting.

Regulatory Mandate for Emergency Action

Immediate medical attention is required upon ingestion of a heavy dose. Regulatory guidance explicitly mandates transporting the affected individual to the nearest hospital casualty or calling a doctor or Poison Control Center immediately. Management for Furazolidone overdosage is entirely symptomatic and supportive, as no specific antidote is available or listed in official labeling. Treatment plans focus on anticipating and managing acute manifestations like seizures and respiratory insufficiency.

Therapeutic Uses of Furoxone

Furoxone is a therapeutic option used in the management of specific gastrointestinal infections. It is utilized for the treatment of conditions caused by susceptible organisms, including certain strains that cause bacterial enteritis and protozoal infections like giardiasis. The primary benefit of Furoxone therapy is to help address the symptoms associated with these enteric infections, such as diarrhea and abdominal discomfort.

Furoxone is considered an intervention for infections caused by sensitive microorganisms. This medication may also be considered in scenarios involving traveler’s diarrhea. It is an approved option that supports the patient's recovery from acute manifestations of the illness.

Quick Fact: Relief for Diarrhea caused by susceptible bacteria and protozoa.

Regulatory References

NIH MedlinePlus Consumer Information on Furazolidone

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Furoxone

The eligibility to use Furoxone (furazolidone) is strictly defined by regulatory authorities based on age, physiological conditions, and potential drug-food constraints.

Eligibility Group
Populations Contraindicated	Infants under 1 month of age are prohibited from use due to the risk of producing hemolytic anemia [RxList]. Patients with a history of hypersensitivity to Furoxone must not use the medicine [RxList].
Condition-Specific Restrictions	G6PD deficiency is a condition that requires caution, as it may lead to mild, reversible hemolysis; the drug must be discontinued if signs of red blood cell breakdown occur [RxList]. Some regulatory sources advise caution for patients with impaired liver or kidney function [Food And Drugs Authority, Ghana].
Age-Related Eligibility	Use is generally approved for adults and children one month of age and older [Mayo Clinic]. No specific data compares Furoxone use in the elderly with use in younger adults [Mayo Clinic].
Pregnancy and Lactation Status	Safety of Furoxone during the childbearing age and pregnancy has not been established, requiring cautious use [RxList]. The medicine is not recommended for use by breastfeeding mothers if the infant is under one month old [E-lactancia].

The official profile establishes non-negotiable prohibitions alongside specific warnings regarding metabolic conditions and the lack of established safety data in vulnerable populations. Eligibility is also constrained by the drug’s MAO-inhibitory properties, which contraindicate concurrent use with certain foods, alcohol, and medicines.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Furoxone (furazolidone) has a significant potential for drug-drug and drug-food interactions due to its property as a Monoamine Oxidase (MAO) inhibitor. This MAO inhibition is documented to persist for up to two weeks after discontinuing the medication.

Contraindicated Combinations

Certain substances must be strictly avoided during Furoxone therapy and for specified periods after treatment. These include:

Indirectly-acting Sympathomimetic Amines: Found in products like nasal decongestants and appetite suppressants, these are contraindicated due to the risk of severe blood pressure increases.
Other MAO Inhibitors: Combining Furoxone with other MAO-acting drugs is contraindicated.
Tyramine-rich Foods and Beverages: These include aged cheeses, fermented or smoked meats, yeast extracts, and certain alcoholic beverages. Consumption is contraindicated because of the risk of hypertensive crisis.

Clinically Significant Interactions

Caution and clinical oversight are required when co-administering Furoxone with other classes of medicines:

Tricyclic Antidepressants (TCAs) and Specific Serotonin-releasing Agents: These combinations may increase the risk of adverse neurological effects.
Alcohol: Ingestion of alcohol or alcohol-containing preparations must be avoided during therapy and for a mandatory four-day period after discontinuation due to the potential for a disulfiram-like reaction (e.g., flushing, breathing difficulty).
Sedatives, Tranquilizers, and Narcotics: These may require reduced dosages when co-administered.
Oral Diabetes Medications and Insulin: Use requires close monitoring for signs of altered blood sugar levels.

Mechanism of Action

Furoxone (furazolidone) is a synthetic nitrofuran derivative. Its antimicrobial action is initiated by its uptake into microbial cells, where it serves as a prodrug. Within the pathogen, the drug's 5-nitro group undergoes a reductive activation process catalyzed by bacterial nitroreductases and other microbial reducing enzymes. This conversion generates highly reactive intermediates (nitroso and hydroxylamine derivatives) and free radicals.

These unstable, reactive species act as non-specific cellular toxicants by covalently binding to and damaging essential macromolecules. A primary molecular target is the bacterial DNA, where the intermediates induce strand breaks and cross-linking, thus inhibiting the necessary processes of DNA replication and transcription. Additionally, the reactive intermediates target and disrupt bacterial enzymes involved in crucial metabolic and energy production pathways, such as those within the Krebs cycle and thiamin utilization. These multiple, non-specific molecular interactions lead to the overall disruption of cellular metabolism and subsequent cell death of the pathogen. Furoxone also functions as an irreversible inhibitor of monoamine oxidase (MAO), which can modulate systemic levels of catecholamines.

Dosage and Administration Information

How to Use Furoxone (Furazolidone) – Official Administration Guidelines

This information describes the mandated procedure for administering Furoxone. It does not include therapeutic uses, safety information, or medical advice.

Administration Scope

Parameter	Instruction
Route of Administration	Oral (by mouth only).
Official Dosage Forms	Tablets and Oral Suspension.
Standard Frequency	Four times daily (Q.I.D.) at evenly spaced intervals (approximately every 6 hours).
Course Duration	The medication must be taken for the full prescribed length, typically 5 to 10 days.
Timing with Meals	May be taken with food if stomach upset occurs.

Procedural and Age-Specific Rules

Dosing Procedure:

The oral suspension must be shaken vigorously before measuring the dose.
The liquid dose must be measured precisely using a specially marked device to ensure accuracy.
For children 5 years or older, the tablet may be crushed and mixed with a spoonful of corn syrup for easier administration.
Do not administer Furoxone to infants younger than one month of age.

Missed Dose: If a dose is missed, take it as soon as remembered; however, if it is near the time for the next scheduled dose, the missed dose should be skipped. Do not take two doses at once.

Summary of Official Use: The official instructions establish a fixed protocol for administration, requiring the medicine to be taken orally four times daily for a non-negotiable duration. This structure is supported by specific procedural steps, such as shaking the liquid and precise measurement, which ensure the correct dosage delivery throughout the entire course, while strictly prohibiting use in infants under one month old.

Recent Clinical Evidence

Research evidence / Overview of studies for Furoxone

Evidence for use in Diarrhea and Bacterial Enteritis

Furoxone has been studied for treating diarrhea and inflammation of the small intestine (enteritis) caused by certain bacterial infections. Research in this area has primarily examined clinical trials where people with conditions associated with acute or disruptive episodes received Furoxone, and their outcomes related to physical discomfort and changes in bowel habits were monitored.

These studies help show what was observed in the patient populations evaluated. Findings describe patterns observed related to changes measured during the study period. However, it is important to remember that these results apply only to the populations studied, and the evidence quality varies across studies.

Research highlights changes measured during the study period concerning symptoms, but it does not determine whether an individual will respond similarly. Furthermore, the specific types of bacteria causing the infection may affect how the treatment was evaluated in these various studies, and comparative evidence is lacking for many common bacteria.

Evidence for use in Giardiasis

Furoxone was evaluated in studies exploring its use against Giardiasis, a parasitic infection characterized by fluctuating or episodic manifestations in the gut. These trials have focused on episodes where symptoms become more noticeable and have tracked patient-reported outcomes describing perceived discomfort and changes in the measure of parasitic presence.

Long-term studies and follow-up

This section will outline the extent of information available regarding the long-term effects of Furoxone. Research has explored what is known about outcomes monitored over an extended period after treatment completion, particularly concerning the durability of the initial treatment response.

Evidence for the effects of Furoxone over months or years after treatment is limited. This means that long-term effects are not fully established, and there is limited information for long-term outcomes regarding the original infection. The available studies primarily look at short-term symptom changes during or immediately after the treatment period.

Evidence in special populations

Furoxone was observed in some studies that specifically looked at its use in certain special populations, such as children. Research describes how symptoms evolved in these specific patient groups compared to general adult populations.

However, data for certain groups, including older adults or individuals with specific comorbid conditions (other existing health issues), remain insufficient. While some research was applied in studies examining patient-reported experiences in children with Giardiasis or bacterial diarrhea, caution is necessary, as sample sizes were modest in these subgroup analyses.

What is still uncertain about Furoxone

This section synthesizes the main evidence gaps and inconsistent findings. Research was observed in some studies to have mixed results across different geographical locations and types of patient populations. This means that findings were mixed, and the certainty remains low in some areas of use.

The main evidence gaps relate to the lack of sufficient data on long-term outcomes and limited information from comparative evidence against newer therapies. Research is still ongoing to fully clarify the precise role of Furoxone in the broader evidence landscape, and data are still emerging regarding its comparative effectiveness. Findings describe group patterns, not personal outcomes, and evidence highlights what is known — and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Furoxone (FAQ)

Q: How quickly does Furoxone start working after the first use?

Official information indicates that the drug is well absorbed after it is taken. However, the active compound has a very short plasma half-life, described in official data as approximately 10 minutes in humans.

Q: Can Furoxone cause strange dreams or sleep problems?

Official safety data sheets note the possibility of sleep disturbance as a potential effect.

Q: Is it normal to feel dizzy or lightheaded when taking Furoxone?

Official product information lists dizziness or lightheadedness as a potential side effect. This may be related to orthostatic hypotension, which is a drop in blood pressure that can occur when standing up quickly. This is a known effect described in regulatory documents.

Q: Are there any known severe side effects that require immediate attention while on Furoxone?

Serious reactions that may require immediate attention include severe blood pressure increases (hypertensive crisis), symptoms of a severe allergic reaction (e.g., swelling, trouble breathing), and hemolytic anemia (destruction of red blood cells) in sensitive individuals. These events are listed because they represent risks that require prompt clinical evaluation.

Q: Is Furoxone safe to use for older people (the elderly)?

Official regulatory documents state that no specific information comparing the use of the drug in the elderly with its use in younger adults is available. The information that defines eligibility and safety applies generally to the adult population.

Q: Are there any specific warnings for people with a history of kidney problems using Furoxone?

Regulatory documents advise that caution should be exercised when the drug is used by patients with a history of impaired kidney or liver function. The official labeling indicates this is a factor for clinical review.

Q: Can Furoxone interact with blood pressure medications?

The drug’s MAO-inhibiting property requires caution. Official labeling requires disclosure of all prescription and nonprescription drugs, including drugs used for blood pressure, to the prescribing professional. Combining the drug with indirectly-acting sympathomimetic amines is contraindicated because they can lead to severe blood pressure increases.

Q: Are there any known long-term effects of using Furoxone repeatedly?

Long-term or chronic use is restricted because high-dose, chronic animal studies showed evidence of tumorigenic activity (the potential to cause tumors). Official health and safety reports also note that limited evidence suggests repeated or long-term occupational exposure may produce cumulative health effects.

Q: What types of infections is Furoxone approved to treat?

The medicine is approved for the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms. It is also used in the treatment of conditions like giardiasis and cholera.

Q: Is there a generic version of Furoxone available?

The brand name Furoxone is discontinued, but generic versions of the active ingredient, Furazolidone, may be available. Furazolidone is the name of the chemical compound in the medicine.

Q: Has Furoxone been studied in large-scale clinical trials?

Studies have examined clinical trials concerning the drug's use in various infections. However, research overviews note that data for certain groups, such as children, were based on modest sample sizes rather than large-scale population studies.

Q: What happens to the drug after it has done its job in the body?

The drug is a prodrug, meaning it becomes active after it is taken. It is quickly metabolized into reactive intermediates and other compounds before being chemically changed and excreted. Most of the byproducts are removed via the urine.

Q: Is it okay to drive or operate machinery while using Furoxone?

Potential side effects of Furoxone include dizziness or lightheadedness. Official documents advise that caution is required with activities that demand mental alertness, due to the potential for such effects.

Q: Why is Furoxone not used as often as some newer antibiotics?

Official reports and literature indicate that in the United States, the drug is no longer marketed because the manufacturer determined the market was too small. This decision contributed to a reduction in its general use compared to other antibiotics.

Q: Is Furoxone described as being primarily excreted by the kidneys?

Pharmacokinetic data indicates that after rapid metabolism, the drug's byproducts are described as being excreted mainly via the urine.

Q: What should I do if my symptoms do not improve after starting Furoxone?

Regulatory information states that persistent or severe symptoms, or lack of expected improvement in your condition, are factors that require communication with a healthcare professional.

Q: Does Furoxone require special monitoring or blood tests?

Special monitoring may be required for certain groups. For patients with G6PD deficiency, regulatory documents require the drug to be discontinued if signs of red blood cell breakdown occur. Additionally, close monitoring is required when co-administered with oral diabetes medications to check for altered blood sugar levels.

Q: Is there a risk of developing a secondary infection while on Furoxone?

There is a risk of developing a secondary infection (superinfection). This can happen when the balance of normal bacteria is changed, potentially leading to the overgrowth of non-susceptible organisms, such as fungi or certain other bacteria (like Clostridioides difficile).

Q: What is the purpose of the black box warning (if any) associated with Furoxone?

While the specific term 'Black Box Warning' is not definitively confirmed on current labels, the drug does carry several major safety restrictions related to severe risks. These restrictions include the risk of hypertensive crisis (due to its MAO-inhibition) and the potential for hemolytic anemia in infants and individuals with certain enzyme deficiencies.

Q: What is the half-life of Furoxone as described in official sources?

Official pharmacokinetic data describes the plasma half-life of the drug as approximately 10 minutes in humans.

How should Furoxone be stored and disposed of?

How to Store and Dispose of Furoxone?

The storage and disposal of Furazolidone (formerly Furoxone) are defined by strict regulatory requirements to maintain product stability and ensure public safety.

Storage Requirement	Official Condition
Temperature	Store at controlled room temperature (15 C to 30 C).
Environment	Keep away from heat, moisture, and direct light.
Handling	Do not freeze. Store in the original, tightly closed, light-resistant container.
Safety	Must be kept out of the sight and reach of children (store locked up).

Official Disposal Instructions

Unused or expired medicine must not be thrown into wastewater or allowed to enter drains. Disposal must strictly adhere to local and national regulations for pharmaceutical waste, ensuring the product is properly discarded and environmental contamination is avoided.

Furoxone